Ergoteles’s PDS Biotechnology PDSB Stock Holding History

Ergoteles’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,000	Closed	-$122K	–	1539
2021 Q4	$122K	Buy	+15,000	New	+$161K	﹤0.01%	1122

Other funds holding PDSB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ergoteles's PDSB Position: Q1 2022 in Review

Ergoteles sold out of PDS Biotechnology (PDSB) in Q1 2022, closing a stake of 15,000 shares — an estimated $122K sold.

Ergoteles first reported a position in PDSB in Q4 2021 and held it in 1 quarter. The position peaked at $122K in Q4 2021. 52 funds tracked by Wall St. Rank hold PDSB as of Q1 2022.

Ergoteles reported no remaining PDS Biotechnology position as of Q1 2022 after selling out during the quarter.
Ergoteles sold 15,000 PDS Biotechnology shares in Q1 2022, an estimated $122K.
Ergoteles first reported a position in PDS Biotechnology in Q4 2021 and held it in 1 quarter.
Ergoteles's PDS Biotechnology position peaked at $122K in Q4 2021.
52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2022.

Based on Ergoteles's 13F filing for Q1 2022, filed 13 May 2022.